Dwelling on Prasugrel: Analysts Debate Prospects for Lilly Clot Drug
This article was originally published in RPM Report
Executive Summary
Eli Lilly & Co. devoted a section of its December 6 investor day specifically to the prospects for prasugrel in light of the widespread interest in the product and the presentation of pivotal trial data (TRITON) a month earlier. Here is a sampling of what analysts took away from the meeting.